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Imidazoline receptors were ﬁrst proposed by Bousquet et al., when they studied antihypertensive eﬀect of clonidine. A strong
candidate for I1R, known as imidazoline receptor antisera-selected protein (IRAS), has been cloned from human hippocampus.
We reported that IRAS mediated agmatine-induced inhibition of opioid dependence in morphine-dependent cells. To elucidate
the functional and structure properties of I1R, we developed the newly monoclonal antibody against the N-terminal hIRAS region
including the PX domain (10–120aa) through immunization of BALB/c mice with the NusA-IRAS fusion protein containing
an IRAS N-terminal (10–120aa). Stable hybridoma cell lines were established and monoclonal antibodies speciﬁcally recognized
full-length IRAS proteins in their native state by immunoblotting and immunoprecipitation. Monoclonal antibodies stained in a
predominantly punctate cytoplasmic pattern when applied to IRAS-transfected HEK293 cells by indirect immunoﬂuorescence
assays and demonstrated excellent reactivity in ﬂow immunocytometry. These monoclonal antibodies will provide powerful
reagents for the further investigation of hIRAS protein functions.
Copyright © 2009 Bo Wang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Imidazoline receptors were ﬁrst proposed by Bousquet et al.,
when they studied antihypertensive eﬀect of clonidine [1].
Based on their physiologic and pharmacological properties,
imidazoline receptors are classiﬁed into three main types:
I1R, I2R, and I3R [2–4]. I1R and I2R have been implicated
in hypertension and psychiatric disorder regulation, respec-
tively, while I3R may be involved in insulin secretion [5–9].
Compared with mitochondrial I2R, which resides within the
monoamine oxidase protein [10], the clonidine-preferring
imidazoline binding sites (known as I1R) are localized to
plasma membrane fractions [11, 12] and speciﬁcally to
synaptic plasma membranes [13].
A strong candidate for I1R, known as imidazoline
receptor antisera-selected protein (IRAS), has been cloned
from human hippocampus [14]. hIRAS is a larger protein of
1504 amino acids consisting of an NH2-terminal phox (PX)
domain, 5 putative leucine-rich repeats, a predicted coiled-
coil domain, and a long COOH-terminal region. Several
evidence supported the identity of native I1R and IRAS
protein in tissue distributions, ligand binding properties,
some cellular functions and downstream signal pathways
[14–18]. The murine form of IRAS, Nischarin, truncated at
the N-terminal 244 amino acids including the PX domain
compared with the hIRAS, was a soluble cytosolic protein
involved in cytoskeletal organization [19]. It has been shown
that decreasing the expression of rat IRAS or Nischarin
in PC12 rat pheochromocytoma cells could attenuate the
activation of extracellular signal-regulated kinase (ERK)
or reduce the radioligand binding to I1R, which further
supported that hIRAS or Nischarin might serve as I1R
itself, or at least a functional subunit of I1R [20]. Recently,
Molderings et al. have reported that the “I1-imidazoline
receptors” mediating eﬀects of clonidine and moxonidine
in PC12 and the transfected HEK293 cells belonged to the
S1P-receptor family, in particular, representing a mixture
of sphingosine-1-phosphate (S1P)1- and S1P3-receptors
and/or heterodimers of both. It was then proposed that
an increased expression of IRAS or Nischarin may improve2 Journal of Biomedicine and Biotechnology
the receptor-traﬃcking from cytosolic S1P-receptors to the
cell membrane and thereby increase the number of binding
sites in the plasma membrane for radioligand binding
[21]. In our previous study, we also reported that IRAS
mediatedagmatine-inducedinhibitionofopioiddependence
in morphine-dependent cells [22]. Despite intensive eﬀorts,
the molecular base of the I1R had not yet been elucidated.
To elucidate the functional and structure properties of
I1R, several diﬀerent epitope-speciﬁc antisera against IRAS
have been raised in rabbits [23]. Because of IRAS splice vari-
ants or nonspeciﬁcity of these antisera, more sizes of IRAS
(≈33, ≈85, ≈170KDa) have been visualized in various tissue
and cells, which limited their uses on western blot. IRAS was
reported to target to the endosomes by a combined action
of a PX domain and a coiled-coil region. The PX domain,
consisting of 10–130 amino acids, was ﬁrst identiﬁed from
the sequence analysis of two SH3 domain-containing cytoso-
lic components of NADPH oxidase, p47phox and p40phox
[24]. Therefore, in the present study, we developed the newly
monoclonal antibody against the N-terminal hIRAS region
including the PX domain (10–120aa). This development
has great utility for immunoblotting, indirect immunoﬂuo-
rescent staining, immunoprecipitation, and ﬂow cytometry.
These monoclonal antibodies will provide powerful reagents
for the further investigation of hIRAS protein functions.
2.MaterialsandMethods
2.1. Generation of the NusA-IRAS(10–120aa) Fusion Protein.
E. coli BL21(DE3) (F-ompT gal dcm hsdSB (rB-mB-)
λ ( D E 3 )( N o v a g e n )c e l l sw e r et r a n s f o r m e dw i t hr e c o m -
binant plasmid, pET43.1-IRAS(10–120aa). Transformants
were selected from ampicillin-containing Luria Bertani
(LB) lates. Selected colonies were cultured in ampicillin-
containing LB media. Isopropyl-β-D-thio galactopyranoside
(IPTG) was added to a ﬁnal concentration of 1mM. The
incubation was continued for 3 hours at 30◦C. Cells were
harvested, mixed with lysis buﬀer (phosphate buﬀered saline
[pH 7.3], 1.0mM EDTA, 1.0mM phenylmethylsulfonyl
ﬂuoride, 0.5mg/mL lysozyme (Roche)), and sonicated.
The high-speed supernatant which contained the pET43.1-
IRAS(10–120aa) soluble protein fraction was loaded onto
10mLNi
2+-NTA agarose columns. The fusion protein was
eluted with lysis buﬀer with 400mM imidazole. Eluted
proteinswereelectrophoresedonSDS-PAGEgels.Expression
yields were analyzed with the Quantity One quantitative
software (Bio-Rad) based on relative band intensities of
comassie blue stains. Puriﬁed proteins were detected with
western blot using anti-His mAbs (Santa Cruz).
2.2. Antiserum Titer Determination by Indirect Enzymelinked
Immunosorbent Analysis (ELISA). The puriﬁed NusA-
IRAS(10–120aa), diluted to 10μg/mL in 50mM carbonate salt
buﬀe r( p H9 . 6 ) ,w a sc o a t e do np l a t e sa t1 0 0μL aliquot per
well, 4◦C overnight. The wells were washed three times
with PBS-Tween buﬀer (0.05% Tween 20 in PBS). The
c o a t e dw e l l sw e r eb l o c k e dw i t h2 0 0 μLo f3 %B S Af o r1
hour at 37◦C and then incubated with 150μL monoclonal
antibodies against NusA-IRAS(10–120aa) fusion protein with
diﬀerent dilutions (from 1 : 1000 to 1 : 25600). After
incubation for 1 hour at 37◦C, the wells were incubated with
150μL horseradish peroxidase-conjugated goat antimouse
IgG (dilution 1 : 5000, Santa Cruz) for 1 hour at 37◦C
after thorough washing. Peroxidase activity was detected
using o-phenylenediamine and H2O2 as enzyme substrates.
Color development was stopped with 2M of H2SO4 and
the absorbance was measured at 490nm using Microplate
Reader (Bio-Rad).
2.3. Production of Antihuman IRAS Monoclonal Antibodies.
The puriﬁed NusA-IRAS(10–120aa) protein (50μgi nav o l u m e
of 80μL) was mixed with an equal volume of Freund’s
complete adjuvant. The antigen-adjuvant mixture was
injected into 6 female BALB/c mice and was followed by
three booster injections at 2-week interval in incomplete
Freund’s adjuvant. The mouse with the highest antibody
titer tested by ELISA was boosted intraperitoneally with
100μgN u s A - I R A S (10–120aa) protein without adjuvant 3 days
before the cell fusion. Feeder layer cells were prepared
1 day prior to fusion. Splenocytes from mice with the
highest ELISA antibody titers were fused with murine
myeloma cells SP2/0 following standard procedures [25].
Culture supernatants were collected after fusion and initially
screened by ELISA with puriﬁed NusA-IRAS(10–120aa) fusion
proteins as antigens. Positive hybridoma clones were selected
with the limiting dilution method, and stable hybridoma
clones were obtained after 3 cloning cycles. Isotypes of
antibodies were identiﬁed with a mouse subisotype panel
(Bio-Rad). The pristine-primed BALB/c mice were injected
intraperitoneally with 1 × 106 hybridoma cells per mouse
in order to acquire abundant mAbs. The ascitic ﬂuid was
collected and mAbs were puriﬁed with a protein A/G aﬃnity
column (Amersham Pharmacia Biotech).
2.4. Western Blotting Analysis. Transfected cells were har-
vested 48 hours after transfection. Total cell lysate prepa-
ration and western blot analysis were performed accord-
ing to previously described procedures [26]. In brief, cell
lysates were prepared, electrophoresed on SDS-PAGE gels,
and transferred to polyvinylidene diﬂuoride (PVDF) mem-
branes. Membranes were blocked with 5% nonfat milk in
TBST (20mM Tris-HCl [pH 7.5], 150mM NaCl, and 0.05%
[v/v] Tween 20) and incubated with IRAS or GFP mAbs
(Cell Signaling Technology Inc). Blots were incubated with
horseradish peroxidase (HRP) conjugated goat antimouse
antibodies (Santa Cruz) after primary antibody incubation,
and blots were developed with enhanced electrochemilumi-
nescence (ECL, Cell Signaling Technology Inc).
2.5. Confocal Microscopy Analysis. The cellular localization
of the IRAS protein was identiﬁed according to previously
described procedures [27]. Cells on glass cover slips were
rinsed with PBS, ﬁxed with 3% paraformaldehyde for
30 minutes, and permeabilized with 0.2% [v/v] Triton
X-100/PBS. Permeabilized cells were incubated with IRAS
mAbs and TRITC-conjugated aﬃnipure goat antimouseJournal of Biomedicine and Biotechnology 3
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Figure 1: Production of immunogens for human IRAS. (a)
Schematic representation of IRAS fusion used for mAb production.
The IRAS N-terminal of the PX domain, and the Arg 10 to Glu
120 were expressed as the NusA fusion protein. LRR represents
the leucine-rich repeats and CC represents the coiled-coiled region.
Numbers represent amino acid positions. (b) Puriﬁcation and
western blot analysis of NusA-IRAS(10–120aa) fusion proteins. SDS-
PAGE analysis after ﬁltration through the Ni
2+-NTA column (left
column) were then immunoblotted with the anti-His mAb (right
column). Sizes (kDa) of molecular mass marker were indicated on
the left side.
IgG (Santa Cruz) for 1 hour for immunoﬂuorescence as-
says. Nuclei were stained with 0.1mg/mL Hoechst33342
(Molecular Probes). Specimens were examined by confocal
ﬂuorescent microscopy on a Bio-Rad Radiance 2100 System.
2.6. Immunoprecipitation Analysis. The HEK293 cells were
transfected with PCMV-myc-IRAS or PCMV-myc plasmid
to analyze IRAS mAbs immunoprecipitated with IRAS. Cell
lysateswerepreparedinamodiﬁedRIPAbuﬀer(50mMTris-
HCl [pH 7.5], 150mM NaCl, 1% [v/v] Nonidet P40, 0.5%
[w/v] sodium deoxycholate) containing Complete Protease
inhibitor Cocktail Tablets (Roche). Cell lysates were cen-
trifuged to remove debris. Recovered lysates were incubated
with IRAS or c-myc mAbs (Santa Cruz) overnight at 4◦C
followed by protein A/G agarose beads (50μL, Santa Cruz)
for another 3 hours to capture the immunoprecipitates.
Recovered immune complexes were extensively washed in
lysis buﬀer. Samples were boiled to release the bound
proteins and appropriate supernatant aliquots were run on
SDS-PAGE gels for western blot analysis as described above.
2.7. Flow Cytometry. Cells (2 × 106)w e r et r a n s f e c t e dw i t h
PCMV-myc-IRAS for each sample and ﬁxed with 70% [v/v]
cold ethanol at 4◦C overnight. Cells were permeabilized
in 0.1% [v/v] Triton X-100/PBS and were incubated with
IRAS or c-myc mAbs (Santa Cruz). Cells were washed
and resuspended in an FITC-conjugated aﬃnipure goat
antimouse IgG (Santa Cruz). Finally, cells were washed twice
and samples were analyzed on a ﬂow immunocytometry
machine (Becton-Dickinson) [28].
2.8. Cell Culture and Transfection. HEK293 cells were grown
in Dulbecco’s modiﬁed Eagle medium (DMEM) (Gibco
BRL) supplemented with 10% fetal bovine serum. Cells were
transfected with diﬀerent plasmid DNAs using a Lipofec-
tamine 2000 (Invitrogen) when cell densities reached 70%
conﬂuence per the manufacturer’s instructions. Hybridoma
cells were grown in DMEM with 10% fetal bovine serum.
2.9. Construction of Expression Vector pET43.1a-IRAS,
pCMV-myc-IRAS, and pEGFPC1-IRAS. The cDNA frag-
ment of the human IRAS N-terminal (10–120aa) was
inserted into the pET-43.1a(+) expression vector (Novagen)
by PCR ampliﬁcation of the human IRAS cDNA (AF082516)
using the following oligomers: sense, 5 -CGGGATCCA-
TGGAGCGGGAAGCCGAGCCG-3 , and antisense, 5 -
CGGAATTCATAGAAGTGAAAATGCAAGAAGTG-3 .The
full-length human IRAS was obtained by PCR ampliﬁcation
of the entire coding region, and the resulting 4512-bp
PCR product was ligated into the pEGPC1 and PCMV-myc
vectors in a similar fashion using the following oligomers,
respectively: sense, 5 -CGCGAATTCTATGGCGACCGC-
GCGCACCTTCG-3 ,and antisense, 5 -CGGGATCCTAGC-
CGGTGAGCTCGACAGGC-3 ,s e n s e ,5  -CGCGAATTC-
GGATGGCGACCGCGCGCACCTTC-3 , and antisense, 5 -
CCGCTCGAGCTAGCCGGTGAGCTCGACAGGC-3 .A l l
plasmid sequences were conﬁrmed by sequencing analysis.
3. Results and Discussion
3.1. Generation of Murine Monoclonal Antibodies (mAbs)
against a Recombinant NusA-IRAS(10–120aa) Fusion Protein.
IRAS is a large protein comprising of 1504 amino acids.
Its NH2-terminal phox domain is important for membrane
association and cellular localization. The N-terminal of IRAS
(10–120aa) covering the PX domain was cloned into the
pET-43.1a(+) (Figure 1(a))[ 29]. The supernatant fusion
protein was puriﬁed by His-tag aﬃnity puriﬁcation and was
subsequently used to generate the monoclonal antibody. The
dissolved protein yielded one major band of 78kDa expected
molecular weight (Figure 1(b)) with high purity and
integrity. The NusA protein used as a control generated the
66kDa expected molecular weight. The recombinant protein
was also conﬁrmed with western blot using anti-His mAbs
(right column, Figure 1(b)). BALB/c mice (n = 3) were
immunized with the NusA-IRAS(10–120aa) fusion protein, and
blood was collected from the mice after multiple injections.
Antibody titers were tested by ELISA on plates coated with
theNusA-IRAS(10–120aa) protein(datanotshown).The2mice4 Journal of Biomedicine and Biotechnology
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Figure 2:VeriﬁcationofthespeciﬁcityoftheIRASmAbs.(a)Identiﬁcationbywesternblotusinganti-HismAborthemAbsDA041,DD015,
BE073, BA022, and AH021 in NusA and NusA-IRAS(10–120aa) recombinant proteins. (b) The whole cell extracts derived from HEK293 cells
were transfected with pEGFPC1-IRAS and the control vector pEGFPC1 plasmid, respectively. Cell lysates were prepared 48 hours after
transfection and were separated by SDS-PAGE. Proteins transferred to PVDF membranes were probed with anti-GFP antibody or the mAbs
DA041, DD015, BE073, BA022, and AH021. Sizes (kDa) of molecular mass marker were indicated on the left side.
with the highest titers were sacriﬁced and spleens from
both mice were fused to myeloma cells following standard
procedures. Individual hybridomas was grown and 125
hybridomas were further characterized. Supernatant from
the growing hybridoma clones was screened with ELISA.
Screening was performed on plates coated with NusA-
IRAS(10–120aa), NusA protein, and GST-IRAS(10–120aa) fusion
protein to determine antibody speciﬁcity. A total of 5
hybridomas (DA041, DD015, BE073, BA022, and AH021)
reacted selectively with the NusA-IRAS(10–120aa) protein in all
3 assays and were further evaluated. Isotype analysis revealed
that all mAbs were of the IgG1 subtype.
The immunoreactivities of the 5 representative mAbs
with NusA-IRAS(10–120aa) were shown in Figure 2,a l lo f
which speciﬁcally recognized a 78kDa protein band which
corresponded to the puriﬁed NusA-IRAS(10–120aa) protein,
but not to the 66kDa NusA protein. Anti-His mAbs reacted
with both proteins in the same experiment (Figure 2(a))a s
controls.WeevaluatedthespeciﬁcityofmAbsinmammalian
cellsbyinsertingIRAScDNAintoexpressionvectorstoallow
the production of GFP fusion proteins under the control of
a CMV promoter. The pEGFPC1 and pEGFPC1-IRAS plas-
mids were separately transfected into HEK293 cells. Western
blot analysis with the anti-GFP antibody demonstrated that
chimeric proteins were expressed and migrated separately at
expected molecular masses of approximately 19 or 27KDa
(Figure 2(b)). However, the expected 190kDa band whose
molecular weight corresponded to the full-length IRAS
protein was only detected with the mAbs DA041, DD015,
and BE073 in GFP-IRAS expressed cells. The remaining
BA022 and AH021 mAbs were negative (Figure 2(b)). The
same samples were also incubated with preimmune serum
with no reactivity (data not shown). Results revealed that all
5 selected mAbs speciﬁcally recognized bacterially expressed
NusA-IRAS(10–120aa) proteins, but only 3 mAbs recognized
recombinant IRAS in mammalian cells.
3.2. Cellular Localization and Flow Cytometry Analysis for
IRAS Expression. IRAS mAbs were used to detect the cellular
localization of IRAS protein based on speciﬁcity character-
ized by western blot analysis. The pEGFPC1-IRAS plasmid
was transfected into HEK293 cells. IRAS protein localization
was tested by ﬂuorescence confocal microscopy after 48
hours transfection. GFP-IRAS was primarily located in the
cytoplasm in a punctate pattern (Figure 3(a)) with concen-
tration onto discrete loci andspot ﬂuorescence(panel A, E, I,Journal of Biomedicine and Biotechnology 5
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Figure 3: Binding of IRAS mAbs to IRAS-expressing cells by immunoﬂuorescence and ﬂow cytometry analysis. (a) HEK293 cells were
transfected with the plasmid pEGFPC1-IRAS. Cellular localization of IRAS was observed by scanning ﬂuorescence confocal microscopy.
GreenrepresentedEGFPﬂuorescence(A,E,I,M,andQ)fromtheGFP-IRASfusionprotein,blue(C,G,K,O,andS)ﬂuorescencerepresented
Hoechst stained cell nuclei, red (B, F, J, N, and R) ﬂuorescence represented cells expressing GFP-IRAS labeled with TRITC-conjugated goat
antimouse antibody using IRAS mAbs as the primary antibody, and yellow (D, H, L, P, and T) represented overlapping green and red
ﬂuorescence. All 3 panels had the same ﬁeld of view. Scale bar, 100μm. (b) Samples were collected and separately analyzed by ﬂow cytometry
fortheabilitytobindthepreimmuneserum(control),thec-mycmAb,andthemAbDA041after48hourstransfectionofPCMV-myc-IRAS.
Results were expressed as histograms with the DNA content on x-axis and the number of ﬂuorescent cells on y-axis. Cells were distributed
in 2 populations, and the second population (R2) with high ﬂuorescence reﬂected the population of transfected cells recognized by the mAb
DA041.6 Journal of Biomedicine and Biotechnology
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Figure 4: Analysis of immunoprecipitates revealed that the IRAS mAbs speciﬁcally recognized the native state of the IRAS protein. The
HEK293 cells were transiently transfected with the empty vector PCMV-myc (negative control) and PCMV-myc-IRAS. Whole cell lysates
werepreparedandimmunoprecipitatedwiththec-mycmAborthemAbsDA041,DD015,BE073,BA022,andAH021.Immunoprecipitation
of the same lysates using mouse normal IgG did not result in the detection of any protein species. Immunocomplexes were analyzed by
western blot with indicated antibodies.
M, and Q), as conﬁrmed in previous studies [30]. The mAbs
DA041, DD015, and BE073 were used as probes to detect a
predominantly punctate cytosolic distribution as expected
(panel B, F, G). However, the mAb BA022 homogenously
detected the ﬂuorescence distribution over the cytoplasm
(panel N) and the mAb AH021 scored negatively (panel
R). Merged images revealed that the GFP-IRAS ﬂuorescence
signiﬁcantly coincided with the immunostaining with mAbs
DA041, DD015, and BE073 (panel D, H, and L), but was
not reﬂected by the mAbs BA022 and AH021 (panel P and
T). Further, the punctate ﬂuorescence patterns appeared
to be unique to the mAbs DA041, DD015, and BE073. In
addition, we also detected the endogenous IRAS protein
with monoclonal antibody DA041 in PC12 cells, showing
a strong signal associated with the membrane and faint
signal in the cytoplasm (data not shown). These results
suggest that the 3 mAbs speciﬁcally detect IRAS proteins by
immunoﬂuorescence, similar to immunoblotting results.
Flow cytometry is a rapid, quantitative, multiparameter
cellular analysis based on the measurement of visible and
ﬂuorescent light emission. We chose the representative mAb
DA041 for further characterization based on the strong sig-
nals detected by immunoblotting and immunoﬂuorescence.
The IRAS cDNA was cloned into the mammalian expression
vector PCMV-myc and was expressed in HEK293 cells. The
mAb DA041 and the c-myc mAb (used as a positive control)
resulted in signiﬁcant increases in ﬂuorescence intensity
when compared to cells incubated with preimmune serum
(Figure 3(b)). The binding eﬃciencies were 30.77% by the
mAb DA041 and 48.26% by the c-myc mAb. No reactivities
were detectable in preimmune sera (0.01%). These results
indicate mAb DA041 is eﬀective for detecting IRAS protein
by ﬂow cytometry.
3.3. MAbs IRAS Immunoprecipitates IRAS from Cell Lysates.
We next characterized IRAS mAb ability to recognize IRAS
proteins in their native states by immunoprecipitation. Cell
extracts were immunoprecipitated with the mAb DA041 and
analyzed with mAb DA041 immunoblotting after 48-hour
transfection with PCMV-myc-IRAS. IRAS was selectively
immunoprecipitatedfromcelllysatesthatexpressedthemyc-
IRAS protein (approximately 175kDa), and those which
corresponded to the predicted size of the full-length IRAS
(Figure 4). Immunoprecipitation of lysates with mouse nor-
mal IgG did not result in detection of protein species. Lysates
were immunoprecipitated with the c-myc mAb to conﬁrm
mAb speciﬁcity, and similarly sized bands were detected.
No corresponding band was visualized when the negative
control c-myc mAb was used to immunoprecipitate cell
lysate of the transfectant expressing the empty PCMV-myc
vector. Similar results were obtained with the mAbs DD015
and BE073 under the same conditions, and the remaining
mAbs BA022 and AH021 scored negatively. Therefore, the 3
isolated antibodies speciﬁcally recognized native full-length
IRAS protein products.
Our results suggested that the mAbs DA041, DD015,
and BE073 were reactive for both immunoﬂuorescence and
immunoblotting. Therefore, these mAbs likely recognized
linear epitopes in the IRAS protein. In addition, the 3 mAbs
were capable of recognition of native full-length IRAS pro-
teins by immunoprecipitation. However, the mAbs BA022
and AH021 speciﬁcally recognized bacterially expressed
IRAS immunogens and did not detect recombinant IRAS in
mammalian cells. This could be related to the diﬀerent IRAS
folding patterns, since misfolded IRAS proteins could result
in the exposure of unique immunogenic epitopes diﬀerent
from native proteins. The mAbs BA022 and AH021 could
be used as backup reagents to safeguard against antibody-
speciﬁcartifacts.Inaddition,analyzingtheoverallhomology
oftheaminoacidsequenceofthePXdomain,SortingNexins
13 (SNX13) is the most relative protein to IRAS [31]. WeJournal of Biomedicine and Biotechnology 7
found monoclonal antibody DA041 against hIRAS could not
react with SNX13 by immunoﬂuorescence assay (data not
shown).Itwasproposedthattheseantibodiesdevelopedhere
were speciﬁc to the PX domain of IRAS.
In summary, we generated speciﬁc mAbs directed aga-
inst the human IRAS N-terminal. The mAb DA041 exhib-
ited the best performance in a variety of assays includ-
ing immunoblotting, immunoprecipitation, indirect immu-
noﬂuorescence stainning, and ﬂow cytometry. Speciﬁc mAbs
may provide an ideal reagent for further investigation of the
function of IRAS proteins.
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